Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Information Update - UPDATE: Mint Pharmaceuticals Inc. recalls all lots of losartan


OTTAWA, ON, Oct. 26, 2021 /CNW/ - Mint Pharmaceuticals Inc. is recalling all lots of its prescription losartan tablets, in 50 mg and 100 mg strengths, after tests found an azido impurity (5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H tetrazole) above the acceptable limit. Long-term exposure to the impurity at levels above what is considered safe could potentially increase the risk of cancer.

Please see the full advisory for more information, including what Canadians should do and Health Canada's work to address the issue of azido impurities found in certain drugs.

Product

Company

DIN

Lot

Expiry

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005006959

April 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005006960

April 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005006961

April 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005006962

April 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005006963

April 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005011154

June 2023

MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389657

2005011156

June 2023

MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389665

2005006807

April 2022

MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389665

2005006808

April 2022

MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389665

2005006809

April 2022

MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS

Mint Pharmaceuticals Inc.

02389665

2005006810

April 2022

MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS 

Mint Pharmaceuticals Inc.

02389665

2105002149

December 2022

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

1805012687

October 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

1805012688

October 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

1805012689

October 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

1805012792

October 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

1905001010

December 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS 

Mint Pharmaceuticals Inc.

02389673

1905001011

December 2021

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005006947

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005006949

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005006950

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005006951

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS 

Mint Pharmaceuticals Inc.

02389673

2005007297

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005007298

April 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2005013776

August 2023

MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS

Mint Pharmaceuticals Inc.

02389673

2105002150

December 2023

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: